Vidaza Injection, Powder, Lyophilized, For Solution
Product Images NDC 59572-102

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Vidaza (NDC 59572-102). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Celgene Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Azacitidinestructuralformula

Chemical structure of azacitidine, the active ingredient in VIDAZA. The diagram shows the molecular arrangement with nitrogen, oxygen, and carbon atoms forming the characteristic structure of this nucleoside analog drug used in injection form.*

FDA Label Image

Image 01

A Kaplan-Meier survival curve chart comparing the proportion of patients surviving over time (in months) from randomization for VIDAZA (azacitidine) versus CCR. The chart includes survival curves labeled AZA and CCR, a table of numbers at risk beneath the time axis, and statistical values such as log-rank p-value, hazard ratio with confidence interval, and death counts for each group.*

FDA Label Image

Principal Display Panel (100 mg Vial Label)

Label for VIDAZA (azacitidine) injection, 100 mg single-use vial. The lyophilized powder is for subcutaneous and intravenous use only. Manufactured by Baxter Oncology GmbH in Germany and Celgene Corporation, Summit, NJ. The label includes storage instructions and cautions for single-use, plus the Celgene logo and NDC 59572-102-01.*

FDA Label Image

Principal Display Panel (100 mg Carton Label)

VIDAZA 100 mg single-use vial packaging label for azacitidine injection, lyophilized powder for solution. Labeled for intravenous and subcutaneous use. Manufactured by Baxter Oncology GmbH, made in Germany, and distributed by Celgene Corporation. Includes NDC 59572-102-01 and barcode. The label states the single-dose vial containing 100 mg azacitidine for injection.*

FDA Label Image

Principal Display Panel (100 mg Vial Label)

The label for VIDAZA (azacitidine) injection, a lyophilized powder for solution. It specifies 100 mg single-use vial intended for subcutaneous and intravenous administration. Manufactured by Celgene Corporation, the label includes storage instructions, dosing information reference, and barcode with product NDC 59572-102-01.*

FDA Label Image

Principal Display Panel (100 mg Carton Label)

VIDAZA 100 mg single-use vial packaging label for azacitidine injection, lyophilized powder for solution. The label states it is for subcutaneous and intravenous use only. Manufactured by BSP Pharmaceuticals, Italy, for Celgene Corporation. Includes NDC 59572-102-01 and Celgene logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.